Analyst consensus rating
Arcturus Therapeutics Holdings Analyst Rating: Buy
ARCT is rated Buy by 10 analysts with a $20.20 target. As of 2026-08-24.
Direct answer
Arcturus Therapeutics Holdings's consensus rating is Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.20.
Forecast evidence checked August 24, 2026.
Get free Arcturus Therapeutics Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.45
- Average price target
- $20.20
- High price target
- $40.00
- Low price target
- $8.00
- Low target gap
- -40.5%
- Target upside
- +50.2%
- High target gap
- +197.4%
- Target range width
- 237.9%
- Consensus rating
- Buy
- Analysts
- 10
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings has a verified Buy consensus. The same dataset has an average price target of $20.20.
How far are Arcturus Therapeutics Holdings's low and high targets from the recorded price?
The low target implies -40.5%, while the high target implies +197.4%.
How many analysts are included in Arcturus Therapeutics Holdings's consensus?
The verified consensus includes 10 analysts.
How is Arcturus Therapeutics Holdings's target upside or downside calculated?
The average target of $20.20 is divided by the recorded price of $13.45, then one is subtracted to produce +50.2%. This does not guarantee a future return.
When was Arcturus Therapeutics Holdings's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.